产品
编 号：F442186
分子式：C13H8Cl4N2O
分子量：350.03
分子式：C13H8Cl4N2O
分子量：350.03
产品类型
规格
价格
是否有货
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 73439-19-7
产品详情
生物活性：
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.
体内研究：
COH-SR4 (5 mg/kg; i.g.; 3x/week; for 6 weeks) reduces body weight and fat mass inhigh fat diet (HFD) obese mice without affecting food intake.COH-SR4 improves glycemic control and dyslipidemia in HFD obese mice.COH-SR4 decreases adipose tissue hypertrophy and affects circulating adipokine levels in HFD obese mice.COH-SR4 prevents hepatic lipid accumulation and fatty liver in HFD obese mice.Animal Model:Nine-week old male C57BL/6J mice
Dosage:5 mg/kg
Administration:Oral gavage, three times a week, for 6 weeks
Result:Decreased body weight and fat mass in HFD obese mice.
体外研究：
COH-SR4 (1-5 μM; 24 hours) results in a dose-dependent increase in the phosphorylation of AMPK and its substrate ACC in 3T3-L1 preadipocytes, as well as in cancer cells such as HL-60, HeLa, MCF-7.COH-SR4 (3-5 μM; 7 days) significantly inhibits 3T3-L1 adipocyte differentiation in a dose-dependent manner.COH-SR4 (1-5 μM; 24 hours) promotes cell G1 cycle arrest.COH-SR4 significantly reduces intracellular lipid accumulation and downregulates the expression of key adipogenesis-related transcription factors and lipogenic proteins.
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.
体内研究：
COH-SR4 (5 mg/kg; i.g.; 3x/week; for 6 weeks) reduces body weight and fat mass inhigh fat diet (HFD) obese mice without affecting food intake.COH-SR4 improves glycemic control and dyslipidemia in HFD obese mice.COH-SR4 decreases adipose tissue hypertrophy and affects circulating adipokine levels in HFD obese mice.COH-SR4 prevents hepatic lipid accumulation and fatty liver in HFD obese mice.Animal Model:Nine-week old male C57BL/6J mice
Dosage:5 mg/kg
Administration:Oral gavage, three times a week, for 6 weeks
Result:Decreased body weight and fat mass in HFD obese mice.
体外研究：
COH-SR4 (1-5 μM; 24 hours) results in a dose-dependent increase in the phosphorylation of AMPK and its substrate ACC in 3T3-L1 preadipocytes, as well as in cancer cells such as HL-60, HeLa, MCF-7.COH-SR4 (3-5 μM; 7 days) significantly inhibits 3T3-L1 adipocyte differentiation in a dose-dependent manner.COH-SR4 (1-5 μM; 24 hours) promotes cell G1 cycle arrest.COH-SR4 significantly reduces intracellular lipid accumulation and downregulates the expression of key adipogenesis-related transcription factors and lipogenic proteins.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备